The rise of GLP-1 medications has reshaped the conversation around obesity treatment. Among them, Ozempic has received extraordinary public attention for its appetite suppressing and weight loss effects. While originally approved for type 2 diabetes, many individuals have used it off label for weight management. But how do patients actually feel about using Ozempic for weight loss outside controlled clinical trials?
A 2026 study published in the Journal of Medical Internet Research offers new insight into this question. The research analyzed real world online reviews to better understand how patients evaluate the benefits and side effects of Ozempic. The findings highlight a powerful theme: for many users, perceived effectiveness matters more than tolerability.
This blog breaks down the study in clear, practical terms and explores what it means for patients, clinicians, and anyone considering Ozempic for weight loss.
Ozempic is a brand name for semaglutide, a GLP 1 receptor agonist that helps regulate blood sugar and appetite. It was first approved by the US Food and Drug Administration for type 2 diabetes management. Another semaglutide formulation, Wegovy, is specifically approved for obesity treatment.
GLP 1 medications work by:
Clinical trials have shown impressive weight loss results, often ranging from about 8 percent to over 15 percent of body weight depending on dose and duration. However, most existing data come from carefully selected trial populations. Real world experiences can differ significantly.
The study, titled Patient Perceptions of Ozempic Semaglutide for Weight Loss: Mixed Methods Analysis of Online Medication Reviews, was published in Volume 28 of the Journal of Medical Internet Research in January 2026.
The researchers wanted to understand:
Researchers analyzed 60 publicly available user reviews from Drugs.com. These were anonymous, self-selected reviews from individuals who indicated they were using Ozempic specifically for weight loss.
This approach is known as infoveillance, which involves analyzing publicly shared digital health narratives to identify patterns in patient experience.
After conducting a thematic analysis, researchers identified three central themes:
Let us explore each in more detail.
Two-thirds of reviewers reported some combination of:
More than half explicitly described losing weight. Many reported dramatic reductions in hunger and food cravings, especially for sugary and greasy foods.
Notably, users who experienced weight loss gave significantly higher satisfaction ratings. Median ratings among this group were well above the overall median.
About 18 percent of reviewers reported minimal weight loss, slow progress, or weight regain after an initial drop. This group was strongly associated with low satisfaction scores and discontinuation plans.
In fact, lack of perceived effectiveness was one of the strongest predictors of negative overall ratings.
Key takeaway: Perceived weight loss effectiveness was the most powerful driver of satisfaction.
The majority of users reported gastrointestinal symptoms such as:
These effects are consistent with what clinical trials have reported for GLP 1 medications.
Interestingly, the presence of gastrointestinal side effects did not significantly influence whether someone rated the drug positively or negatively. Both high and low rating groups reported similar rates of nausea and digestive discomfort.
This suggests many users were willing to tolerate gastrointestinal symptoms if they were losing weight.
Non-gastrointestinal symptoms were also reported, including:
These side effects were more strongly associated with low satisfaction scores.
In some reviews, individuals described serious complications requiring emergency care. Although the study could not verify medical causality, these experiences clearly shaped patient perceptions.
Two reviewers mentioned depressive symptoms that they attributed to Ozempic use. While rare in this dataset, concerns about mental health effects have been discussed more broadly in relation to GLP 1 medications.
The study emphasizes that further research is needed to clarify whether there is a causal link between semaglutide and mood changes.
Among users who explicitly stated they planned to continue treatment:
This is a critical finding. Even when side effects were present, patients who perceived meaningful weight loss were willing to continue.
Among those who planned to stop:
Importantly, statistical analysis showed that discontinuation was more closely linked to lack of effectiveness than to gastrointestinal discomfort alone.
In simple terms, users were more likely to tolerate nausea than tolerate no results.
If you are exploring Ozempic for weight loss, this study offers several insights:
Understanding that:
can help set realistic expectations.
Many users are willing to manage temporary discomfort if they see tangible results. If weight loss stalls, frustration may increase, especially when side effects continue.
Serious side effects, though less common, were described in some reviews. Ongoing medical supervision is essential when using GLP-1 medications.
For healthcare providers, this study highlights several key considerations:
By focusing on expectation setting and personalized monitoring, clinicians may improve adherence and reduce premature discontinuation.
Because data were anonymous and publicly posted, researchers could not verify claims or gather additional clinical context.
Traditional clinical trials remain essential for evaluating safety and efficacy. However, they often exclude certain populations and operate under tightly controlled conditions.
Infoveillance studies add value by:
This approach can complement randomized controlled trials and inform patient-centered care strategies.
The rapid rise of semaglutide and other GLP-1 medications reflects a broader shift in how obesity is treated. Pharmacotherapy is increasingly recognized as a legitimate medical tool rather than a last resort.
At the same time, public enthusiasm can outpace scientific nuance. Online narratives provide insight into how people weigh trade-offs between benefits and side effects in everyday life.
This 2026 study shows that, for many users, results speak louder than discomfort.
The 2026 analysis published in the Journal of Medical Internet Research provides a clear message:
For individuals considering Ozempic for weight loss, informed decision-making should involve:
As GLP 1 medications continue to evolve, integrating clinical evidence with patient reported experience will be critical in shaping future obesity care.
Armanious AJ, Hunter RM, Griffiths KR, Bowrey HE, Brown RM, James MH. Patient Perceptions of Ozempic Semaglutide for Weight Loss: Mixed Methods Analysis of Online Medication Reviews. Journal of Medical Internet Research. 2026;28:e78391. doi:10.2196/78391.
This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Ozempic and other semaglutide medications should only be used under the supervision of a qualified healthcare professional. Individual results vary, and risks, benefits, and alternatives should be discussed with your provider before starting or stopping any medication.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.